Read by QxMD icon Read

Clinical and Applied Thrombosis/hemostasis

Margaret Prechel, Susan Hudec, Elizabeth Lowden, Vicki Escalante, Nicholas Emanuele, Maryann Emanuele, Jeanine M Walenga
Heparin (H) anticoagulation in populations characterized by elevated platelet factor 4 (PF4) frequently elicits PF4/H antibodies, presenting a risk of heparin-induced thrombocytopenia. Recent studies have shown that anti-PF4/H enzyme-linked immunosorbent assays (ELISAs) detect antibodies in individuals never exposed to heparin. Platelet factor 4/H cross-reactive antibodies may result from PF4-mediated defense responses to injury or infection. This study questioned whether patients with diabetes are more likely to develop the endogenous cross-reactive antibodies...
November 12, 2018: Clinical and Applied Thrombosis/hemostasis
Mercedes de León Bautista, Mirza Romero-Valdovinos, Beatriz Zavaleta-Villa, Arony Martínez-Flores, Angélica Olivo-Díaz
Preeclampsia (PE) is a pregnancy disorder that increases maternal and fetal morbidity and mortality worldwide. High plasma levels of homocysteine (Hcy) are a risk factor for several cardiovascular diseases. Cystathionine β-synthase (CBS) plays an important role in Hcy homeostasis catalyzing the irreversible degradation of Hcy to cystathionine, protecting the endothelium from injury caused by hypoxia. Several mutations and polymorphisms may alter the expression of the CBS gene, resulting in variable levels of Hcy...
October 31, 2018: Clinical and Applied Thrombosis/hemostasis
Paul C Moorehead, Anthony K C Chan, Brigitte Lemyre, Rochelle Winikoff, Heather Scott, Sue Ann Hawes, Manohar Shroff, Aidan Thomas, Victoria E Price
Newborns with hemophilia are at risk of intracranial hemorrhage, extracranial hemorrhage, and other bleeding complications. The safe delivery of a healthy newborn with hemophilia is a complex process that can begin even before conception, and continues throughout pregnancy, birth, and the newborn period. This process involves the expectant parents and a wide variety of health-care professionals: genetic counselors, obstetricians, neonatologists, pediatricians, radiologists, adult and pediatric hematologists, and nurses with expertise in hemophilia...
October 29, 2018: Clinical and Applied Thrombosis/hemostasis
Wei-Ying Jen, Young Seok Jeon, Pipin Kojodjojo, Eleen Hui Er Lee, Ya Hui Lee, Yi Ping Ren, Teng Jie Shawn Tan, Yang Song, Tianjiao Zhang, Lynette Teo, Mengling Feng, Yen-Lin Chee
Pulmonary embolism (PE) is associated with mortality. There are many clinical prediction tools to predict early mortality in acute PE but little consensus on which is best. Our study aims to validate existing prediction tools and derive a predictive model that can be applied to all patients with acute PE in both inpatient and outpatient settings. This is a retrospective cohort study of patients with acute PE. For each patient, the Pulmonary Embolism Severity Index (PESI), simplified PESI (sPESI), European Society of Cardiology (ESC), and Angriman scores were calculated...
October 28, 2018: Clinical and Applied Thrombosis/hemostasis
Jack Bontekoe, Justin Lee, Vinod Bansal, Mushabbar Syed, Debra Hoppensteadt, Paula Maia, Amanda Walborn, Jeffrey Liles, Eugene Brailovsky, Jawed Fareed
Atrial fibrillation (AF) is prevalent in nearly 27% of patients with stage 5 chronic kidney disease on hemodialysis (CKD5-HD), suggesting a strong association between these 2 pathologies. It is hypothesized that the relationship between these 2 diseases may be mediated by inflammation. Angiopoietin-2 (Ang-2), a pro-inflammatory biomarker of endothelial instability, inflammation, and vascular remodeling, is elevated in CKD5-HD and AF, yet has not been evaluated in patients with concomitant AF and CKD5-HD. The aim of this study is to analyze circulating levels of inflammatory and thrombotic biomarkers in patients with concomitant AF and CKD5-HD...
October 28, 2018: Clinical and Applied Thrombosis/hemostasis
Justin Lee, Jack Bontekoe, Brandon Trac, Vinod Bansal, José Biller, Debra Hoppensteadt, Paula Maia, Amanda Walborn, Jawed Fareed
Patients with stage 5 chronic kidney disease (CKD5D) have a higher risk of developing neurocognitive deficits. Stroke, cervical carotid artery disease (CCAD), and intracranial atherosclerotic disease (ICAD) are causes of such deficits in CKD5D. Chronic inflammation from renal failure elevates risk for these diseases through oxidative stress and vascular dysfunction. The adverse impact on the carotid and intracranial vasculatures contributes to the multifactorial pathophysiology of stroke. Eleven plasma biomarker levels in patients with CKD5D (n = 97) and healthy controls (n = 17-50) were measured using sandwich enzyme-linked immunosorbent assay (ELISA) method...
October 22, 2018: Clinical and Applied Thrombosis/hemostasis
Ahmed El-Bardissy, Hazem Elewa, Shaban Mohammed, Ahmed Shible, Rizwan Imanullah, Abdul Moqeeth Mohammed
Direct oral anticoagulants (DOACs) are more commonly prescribed since their introduction. Reports on inappropriate prescribing have been observed which may indicate poor awareness on these agents. In this study, we aim to evaluate the extent of the physicians' knowledge on DOACs and its possible impact on physicians' confidence to prescribe these medications. A prospective cross-sectional survey was developed based on the literature review. Eligible participants were physicians and surgeons currently practicing at Hamad General Hospital in Qatar...
October 22, 2018: Clinical and Applied Thrombosis/hemostasis
Xiangyu Wu, Chen Gong, Justin Weinstock, Jun Cheng, Shengnan Hu, Scott A Venners, Yi-Hsiang Hsu, Suwen Wu, Xiangdong Zha, Shanqun Jiang, Yong Li, Faming Pan, Xiping Xu
Our goal was to examine the associations of the 388A>G and 521T>C polymorphisms in the solute carrier organic anion transporter 1B1 (SLCO1B1) gene with hepatic function, baseline lipid levels, and the lipid-lowering efficiency of simvastatin. We recruited 542 patients with hyperlipidemia. The 388A>G and 521T>C polymorphisms were genotyped. Serum alanine aminotransferase (ALT) and aspartate transaminase (AST), Serum triglyceride (TG), total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), and high-density lipoprotein cholesterol (HDL-C) levels were measured before and after an oral 20-mg dose of simvastatin...
October 18, 2018: Clinical and Applied Thrombosis/hemostasis
Werner Rath, Georg-Friedrich von Tempelhoff, Panagiotis Tsikouras
No abstract text is available yet for this article.
October 16, 2018: Clinical and Applied Thrombosis/hemostasis
Asmaa M Zahran, Omnia El-Badawy, Ismail L Mohamad, Deiaaeldin M Tamer, Safwat M Abdel-Aziz, Khalid I Elsayh
Hyperglycemia alone may not explain the increased risk of cardiovascular diseases (CVDs) in patients with type 1 diabetes (T1D) compared with type 2. This study emphases on the evaluation of some platelet activity markers in patients with T1D, with relevance to some metabolic disorders as hyperlipidemia and hyperglycemia. This study was performed on 35 patients with T1D and 20 healthy controls. All participants were subjected to full history taking, clinical examination and assay of glycated hemoglobin (HbA1c ), and lipid profile...
October 11, 2018: Clinical and Applied Thrombosis/hemostasis
Ichiro Wakabayashi, Naomi Mambo, Takahiro Ueda, Daisuke Nonaka, Lyang-Ja Lee, Kenji Tanaka, Joji Kotani
Complication of disseminated intravascular coagulation (DIC) is a determinant of the prognosis for patients with sepsis. The purpose of this study was to find DIC-related peptides in blood for prediction and early diagnosis of DIC in patients with sepsis. The participants were 20 patients with sepsis (age: 68.9 ± 11.4 years) and they were divided into 2 groups with (n = 8) and without (n = 12) a complication of DIC. Peptides in the serum of the patients were inclusively analyzed by a new method for peptidome analysis using a target plate, BLOTCHIP...
October 10, 2018: Clinical and Applied Thrombosis/hemostasis
Yaqiong Tang, Xinyou Zhang, Shiyu Han, Tiantian Chu, Jiaqian Qi, Hong Wang, Xiaowen Tang, Huiying Qiu, Chengcheng Fu, Changgeng Ruan, Depei Wu, Yue Han
Severe thrombocytopenia is a serious condition that frequently arises in patients with myelodysplastic syndrome (MDS) and is associated with poor prognosis. Few studies have investigated the prognostic significance of platelet recovery in patients with MDS having thrombocytopenia. We retrospectively analyzed 117 patients with de novo MDS complicated with thrombocytopenia (platelet count [PLT] < 100 × 109 /L). Patients received decitabine treatment (schedule A) or decitabine followed by allogeneic hematopoietic stem cell transplantation (allo-HSCT; schedule B)...
October 8, 2018: Clinical and Applied Thrombosis/hemostasis
Chrysoula Papageorgiou, Georges Jourdi, Eusebe Adjambri, Amanda Walborn, Priya Patel, Jawed Fareed, Ismail Elalamy, Debra Hoppensteadt, Grigoris T Gerotziafas
Disseminated intravascular coagulation (DIC) is an acquired clinicobiological syndrome characterized by widespread activation of coagulation leading to fibrin deposition in the vasculature, organ dysfunction, consumption of clotting factors and platelets, and life-threatening hemorrhage. Disseminated intravascular coagulation is provoked by several underlying disorders (sepsis, cancer, trauma, and pregnancy complicated with eclampsia or other calamities). Treatment of the underlying disease and elimination of the trigger mechanism are the cornerstone therapeutic approaches...
October 8, 2018: Clinical and Applied Thrombosis/hemostasis
Genevieve Claire Moyer, Bethany Samuelson Bannow, Courtney Thornburg, Rachel Rosovsky, Tzu-Fei Wang, Scott Woller, Dianne Thornhill, Lisa Baumann Kreuziger
Venous thromboembolism (VTE) is a highly morbid condition with several available oral anticoagulant treatment options. Numerous studies have been published comparing warfarin to direct oral anticoagulants; however, several populations remain underrepresented in these reports. We surveyed members of The Venous ThromboEmbolism Network U.S. working group regarding their oral anticoagulant preferences for the treatment of VTE in different and challenging populations. In individuals with VTE and no other medical comorbidities, respondents preferred either rivaroxaban (48...
October 2, 2018: Clinical and Applied Thrombosis/hemostasis
Juraj Sokol, Maria Skerenova, Kamil Biringer, Tomas Simurda, Peter Kubisz, Jan Stasko
The aim of our study was to evaluate GP6 gene in patients with sticky platelet syndrome (SPS) and fetal loss. Platelet aggregability was tested with platelet-rich plasma using PACKS-4 aggregometer (Helena Laboratories). High-resolution melting analysis on LightCycler 480 II (Roche Diagnostics) was used for single-nucleotide polymorphism (SNP) genotyping. We examined 64 patients with SPS and 54 control participants. We found significantly higher occurrence of 5 SNPs in patients with SPS versus controls (rs1671152, rs1654433, rs1613662, rs1654416, and rs2304167)...
October 2, 2018: Clinical and Applied Thrombosis/hemostasis
Elias Kyriakou, Konstantinos Katogiannis, Ignatios Ikonomidis, George Giallouros, Georgios K Nikolopoulos, Evdoxia Rapti, Maria Taichert, Katerina Pantavou, Argiri Gialeraki, Foteini Kousathana, Aristarchos Poulis, Andreas G Tsantes, Stefanos Bonovas, Violetta Kapsimali, Georgios Tsivgoulis, Argirios E Tsantes
Our aim is to determine the most appropriate laboratory tests, besides anti-factor Xa (anti-FXa) chromogenic assays, to estimate the degree of anticoagulation with apixaban and compare it with that of rivaroxaban in real-world patients. Twenty patients with nonvalvular atrial fibrillation treated with apixaban 5 mg twice daily and 20 patients on rivaroxaban 20 mg once daily were studied. Conventional coagulation tests, thrombin generation assay (TGA), and thromboelastometry (nonactivated TEM [NATEM] assay) were performed in the 40 patients and 20 controls...
October 1, 2018: Clinical and Applied Thrombosis/hemostasis
Jen-Hung Huang, Yung-Kuo Lin, Cheng-Chih Chung, Ming-Hsiung Hsieh, Wan-Chun Chiu, Yi-Jen Chen
Rivaroxaban, a direct factor Xa inhibitor, is widely used to reduce the chance of stroke in patients with atrial fibrillation (AF). It is not clear why the prothrombin time (PT) of the international normalized ratio (INR) fails to correlate with treatment using rivaroxaban in patients with AF. In this study, patient characteristics, the rivaroxaban dosage, AF type, drug history, biochemical properties, and hematological profiles were assessed in patients treated with rivaroxaban. In 69 patients with AF receiving rivaroxaban, 27 (39...
September 24, 2018: Clinical and Applied Thrombosis/hemostasis
Diana M Sobieraj, William L Baker, Eni Smith, Katarzyna Sasiela, Stephanie E Trexler, Oliver Kim, Craig I Coleman
To perform a systematic review and network meta-analysis evaluating the efficacy and safety of low-molecular-weight heparins (LMWHs), vitamin K antagonists (VKAs), and direct-acting oral anticoagulants (DOACs) for the treatment of cancer-associated thrombosis (CAT). We searched MEDLINE, Cochrane Central Register of Controlled Trials, and conference abstracts through March 2018. Randomized controlled trials (RCTs) enrolling adults with CAT comparing 2 or more full-dose anticoagulants (LMWH, VKA, and DOAC) and evaluating recurrent venous thromboembolism (VTE), major bleeding, and/or all-cause mortality were included...
September 24, 2018: Clinical and Applied Thrombosis/hemostasis
Wen-Ya Lin, Jiaan-Der Wang, Yu-Tse Tsan, Wei-Cheng Chan, Kwok-Man Tong, Shin-Tsu Chang, Yuan-Yang Cheng
Recurrent hemarthrosis in patients with hemophilia (PWH) results in chronic arthropathy requiring total joint replacement (TJR). This study aimed to compare the difference in TJR rate between patients with hemophilia A (HA) and hemophilia B (HB). A final total of 935 PWH (782 HA and 153 HB) without inhibitors were collected from the Taiwan's National Health Insurance Research Database between 1997 and 2013. Demographics, clinical characteristics, and TJR rate were compared between the 2 groups. The annual use of clotting factor concentrate was not different between HA and HB groups ( P = ...
September 13, 2018: Clinical and Applied Thrombosis/hemostasis
Clara Ting, Katelyn W Sylvester, James W Schurr
Due to variable pharmacokinetic properties, therapeutic anticoagulation with continuous unfractionated heparin (UFH) requires ongoing laboratory monitoring, generally with activated partial thromboplastin time (aPTT). In the ambulatory setting, clinicians who manage warfarin therapy often use time in the therapeutic range (TTR) to estimate a percentage of time the international normalized ratio is therapeutic. We applied the TTR concept to aPTT monitoring for therapeutic UFH and used 2 methodologies for estimation: percentage of aPTT values in range (%aIR) and a modification of the Rosendaal method (mod-Rosendaal)...
September 13, 2018: Clinical and Applied Thrombosis/hemostasis
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"